ArticleCell2018
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2,494 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2,494 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk.Nature communications · 2026Pooled it
- Genome-wide meta-analysis across East Asian and European populations provides insights into the molecular basis of lung cancer.Genome medicine · 2026Pooled it
- Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology.Signal transduction and targeted therapy · 2026Trial
- Allele-resolved monosome and polysome sequencing identifies cis-variants affecting mRNA translation.Life science alliance · 2026Article
- Pan-Cancer Gene Expression Predicts Per-Cancer Radiation Therapy Response.Advances in radiation oncology · 2026Article
- Elevated DOCK4 expression correlates with favorable prognosis and immune infiltration in clear cell renal cell carcinoma.Annals of medicine · 2026Article
- A common germline 3' UTR variant controls DDIT4 translation efficiency and stress responses in cancer cells.iScience · 2026Article
- Dynamic single-cell landscape reveals a T-cell-suppressed microenvironment and a conserved neutrophil program in the lung metastatic niche.Genes & diseases · 2026Article
- A single-cell atlas of human neutrophils reveals neutrophil heterogeneity across health and disease.Nature immunology · 2026Article
- Androgen Receptor (AR) Expression is Associated with an Immune-Cold Phenotype and Reduced Response to Immune Checkpoint Inhibitors in ER-Positive/HER2-Negative Breast Cancer.Annals of surgical oncology · 2026Article
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- Comprehensive characterization of transposable element expression reveals regulatory circuitry and clinical implications in cancers.Science advances · 2026Article
- Cancers modulate processing and presentation of p53 neoantigens to evade T cell detection.Immunity · 2026Article
- Article
- Integrative multi-omics profiling of insomnia-related molecular features reveals microbiome, immune, and therapy-relevant heterogeneity in colorectal cancer.Microbiology spectrum · 2026Article
- CWH43 Suppresses Ferroptosis-Associated Vulnerability Through Redox Adaptation in Colorectal Cancer.International journal of molecular sciences · 2026Article
- High-Risk Rhabdomyosarcomas Feature a Convergent Cell State.Cancer research · 2026Article
- Article
- A transcriptional signature of resting mast cells is associated with improved disease outcome in HRGenes and immunity · 2026Article
- Pan-cancer characterization of the pyrimidine catabolic enzyme UPB1 identifies a tumor-suppressive prognostic biomarker in skin cutaneous melanoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
2,434 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.